PL3065761T3 - Sposób leczenia schorzeń oczu za pomocą darpinu przeciwko vegf - Google Patents

Sposób leczenia schorzeń oczu za pomocą darpinu przeciwko vegf

Info

Publication number
PL3065761T3
PL3065761T3 PL14802544T PL14802544T PL3065761T3 PL 3065761 T3 PL3065761 T3 PL 3065761T3 PL 14802544 T PL14802544 T PL 14802544T PL 14802544 T PL14802544 T PL 14802544T PL 3065761 T3 PL3065761 T3 PL 3065761T3
Authority
PL
Poland
Prior art keywords
eye
treating conditions
vegf darpin
darpin
vegf
Prior art date
Application number
PL14802544T
Other languages
English (en)
Polish (pl)
Inventor
Thomas Hohman
Janet Cheetham
Scott Whitcup
Erik Lippa
Original Assignee
Allergan, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan, Inc. filed Critical Allergan, Inc.
Publication of PL3065761T3 publication Critical patent/PL3065761T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PL14802544T 2013-11-05 2014-11-04 Sposób leczenia schorzeń oczu za pomocą darpinu przeciwko vegf PL3065761T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361900246P 2013-11-05 2013-11-05
US201462016620P 2014-06-24 2014-06-24
PCT/US2014/063951 WO2015069668A1 (en) 2013-11-05 2014-11-04 Method of treating conditions of the eye with an anti-vegf darpin
EP14802544.8A EP3065761B1 (en) 2013-11-05 2014-11-04 Method of treating conditions of the eye with an anti-vegf darpin

Publications (1)

Publication Number Publication Date
PL3065761T3 true PL3065761T3 (pl) 2020-05-18

Family

ID=51947485

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14802544T PL3065761T3 (pl) 2013-11-05 2014-11-04 Sposób leczenia schorzeń oczu za pomocą darpinu przeciwko vegf

Country Status (14)

Country Link
US (4) US20150126458A1 (OSRAM)
EP (2) EP3065761B1 (OSRAM)
JP (3) JP2016536369A (OSRAM)
KR (1) KR20160070164A (OSRAM)
CN (1) CN105960247A (OSRAM)
AU (2) AU2014346921A1 (OSRAM)
CA (1) CA2927012A1 (OSRAM)
DK (1) DK3065761T3 (OSRAM)
ES (1) ES2773317T3 (OSRAM)
HU (1) HUE047910T2 (OSRAM)
PL (1) PL3065761T3 (OSRAM)
PT (1) PT3065761T (OSRAM)
TW (1) TWI729970B (OSRAM)
WO (1) WO2015069668A1 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007237096C1 (en) 2006-04-07 2012-12-13 EyePoint Pharmaceuticals, Inc. Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof
US20130095065A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for Treating Vascular Leak Syndrome and Cancer
US10568934B2 (en) 2012-05-07 2020-02-25 Allergan, Inc. Method of treating AMD in patients refractory to anti-VEGF therapy
BR112020022610A2 (pt) 2018-05-10 2021-02-09 Regeneron Pharmaceuticals, Inc. proteína de fusão de receptor de vegf de alta concentração que contém formulações
JP7695187B2 (ja) 2018-09-24 2025-06-18 アイポイント ファーマシューティカルズ, インコーポレイテッド HPTP-β(VE-PTP)およびVEGFを標的にする多特異性抗体
BR112021024231A2 (pt) * 2019-06-04 2022-04-26 Molecular Partners Ag Proteínas de ligação fap recombinantes e uso da mesma
EP4225796A4 (en) 2020-10-07 2024-11-13 Line 6 Biotechnology, Inc Methods and agents for the treatment of ocular disease
WO2022074623A1 (en) 2020-10-08 2022-04-14 Notal Vision Ltd. Oct guided therapy
CN114075290B (zh) * 2022-01-20 2022-04-19 南京鼓楼医院 Cd40靶向结合蛋白、其编码核酸以及用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0011407B8 (pt) 1999-06-08 2021-05-25 Regeneron Pharma molécula de ácido nucléico quimérica, polipeptídeo de fusão, vetor de expressão, sistema de vetor hospedeiro, e, métodos de produzir um polipeptídeo de fusão
JP5291279B2 (ja) 2000-09-08 2013-09-18 ウニヴェルジテート・チューリッヒ 反復モジュールを含む反復タンパク質の集合体
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
EP1996220B2 (en) 2006-03-06 2023-08-16 Amunix Operating Inc. Unstructured recombinant polymers and uses thereof
WO2008097497A2 (en) 2007-02-02 2008-08-14 Adnexus, A Bristol-Myers Squibb R & D Company Vegf pathway blockade
ES2362386T3 (es) 2007-06-21 2011-07-04 Technische Universität München Proteínas activas biológicas que tienen estabilidad aumentada in vivo y/o in vitro.
CN102272148A (zh) * 2008-11-03 2011-12-07 分子组合公司 抑制vegf-a受体相互作用的结合蛋白
TWI510246B (zh) 2010-04-30 2015-12-01 Molecular Partners Ag 抑制vegf-a受體交互作用的經修飾結合性蛋白質
US10568934B2 (en) * 2012-05-07 2020-02-25 Allergan, Inc. Method of treating AMD in patients refractory to anti-VEGF therapy

Also Published As

Publication number Publication date
DK3065761T3 (da) 2020-02-17
TWI729970B (zh) 2021-06-11
JP2016536369A (ja) 2016-11-24
US20150126458A1 (en) 2015-05-07
US20210008158A1 (en) 2021-01-14
EP3628324A1 (en) 2020-04-01
KR20160070164A (ko) 2016-06-17
EP3065761A1 (en) 2016-09-14
PT3065761T (pt) 2020-02-21
TW201609125A (zh) 2016-03-16
US20220175881A1 (en) 2022-06-09
WO2015069668A1 (en) 2015-05-14
JP2022107628A (ja) 2022-07-22
AU2020202968A1 (en) 2020-05-21
US20170157207A1 (en) 2017-06-08
EP3065761B1 (en) 2020-01-08
ES2773317T3 (es) 2020-07-10
HUE047910T2 (hu) 2020-05-28
JP2020169191A (ja) 2020-10-15
CN105960247A (zh) 2016-09-21
CA2927012A1 (en) 2015-05-14
AU2014346921A1 (en) 2016-06-02

Similar Documents

Publication Publication Date Title
IL286808A (en) System and methods for ocular injection
IL278018A (en) Methods for the treatment or prevention of ophthalmological conditions
EP2991729B8 (en) Systems for the treatment of eye conditions
DK3057993T3 (en) Method for Treating Conditions Associated with MASP-2 Dependent Complement
PL3065761T3 (pl) Sposób leczenia schorzeń oczu za pomocą darpinu przeciwko vegf
SG11201601412XA (en) Compositions and methods for the treatment of presbyopia
ZA201706059B (en) Method of treatment with tradipitant
IL252475B1 (en) Method and devices for optical symmetrization of a pupil
PL3023308T3 (pl) Element okładziny wewnętrznej oraz sposób jego wytwarzania
PL3027564T3 (pl) Kocioł do topienia ze spalaniem zanurzeniowym i sposób
IL251769A0 (en) Methods for treating eye conditions
IL254825A0 (en) Methods of treatment with Tesalisib
GB201421861D0 (en) Method of aquiring fuel injector characteristics
EP3079679A4 (en) Method of treatment of alopecia with monoterpenoids
IL241096B (en) Treatment methods
GB201501315D0 (en) Submerged combustion melters and methods
SG10201802808SA (en) Method of treating ocular disorders
PL3131549T3 (pl) Sposób leczenia zaburzeń ruchowych przy użyciu befiradolu
PT2836176T (pt) Técnica para tratar presbiopia
EP3046571A4 (en) COMPOSITIONS AND METHODS FOR TREATING CONDITIONS ASSOCIATED WITH y-HERPESVIRUSES
GB201317835D0 (en) Bottle and method for the introduction of an additive into a central heating radiator
GB201322778D0 (en) Method of treatment
GB201314882D0 (en) Method of treatment